Advances of Sirolimus in the Treatment of Patients with Autoimmune Cytopenia---Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1667-1670, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-922314
ABSTRACT
Autoimmune cytopenia is a general term for all hemocytopenia diseases caused by humoral or cellular immunity abnormalities, and its common immune mechanism determines the importance of immunosuppressive therapy. Sirolimus, as an immunosuppressant against of mTOR, induces immune tolerance by adjusting Treg cells, which has application prospect in the treatment of refractory autoimmune cytopenia. This article reviews the mechanism, application, and possible adverse reactions of sirolimus in the treatment of idiopathic autoimmune cytopenia.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Trombocitopenia
/
Linfocitos T Reguladores
/
Sirolimus
/
Inmunosupresores
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS